Antibody-drug conjugate

Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients

Retrieved on: 
Tuesday, May 3, 2022
Antibody, U.S. Securities and Exchange Commission, Sciatica, ADC, Society, Phase, Forward-looking statement, Private Securities Litigation Reform Act, PFS, Pain, GLOBE, Conjugation, Antibody-drug conjugate, Safety, Patient, Autoimmune disease, Security (finance), Trial of the century, Risk, Kensington Security Slot, RTX, FDA, CSCO, Cancer, HER2/neu, Annual report, Trastuzumab emtansine, Osteoarthritis, Progression-free survival, Vaccine, Trigeminal neuralgia, PHN, Kelun, Conference, TRPV1, SAN, ORR, Therapy, Fine chemical, Pharmaceutical industry, COVID-19

A166 has demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.

Key Points: 
  • A166 has demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.
  • Program for SEMDEXA, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022.
  • Forward-looking statements include statements regarding A166 (Anti-HER@-ADC); the therapeutic and clinical potential of A166, including its antitumor activity; the potential safety and efficacy of A166 and the clinical testing of A166.

GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate

Retrieved on: 
Tuesday, April 19, 2022
CEO, CTO, FIC, Clinical trial, IND, Samsung Medical Center, CNS, Brain, SMC, Patient, Founder, Technology, Antibody-drug conjugate, Cytotoxicity, LDC, Antibody, Partnership, Quality of life, Cancer, ADC, Neurological disorder, Therapy, D, Pharmaceutical industry, Fine chemical, Vaccine

GeneQuantum focuses on next generation Antibody Drug Conjugate (ADC) development.

Key Points: 
  • GeneQuantum focuses on next generation Antibody Drug Conjugate (ADC) development.
  • GeneQuantum is excited about the significant potential of partnerships with business partners and will continue to expand its deal pipeline in the antibody drug conjugate (ADC) and protein therapeutic market.
  • Gang Qin, the Founder & Chairman, CEO of GeneQuantum, commented: "As an innovative antibody+ company, we look for complementary partners to maximize value of our platform technology.
  • After evaluating the data, the linker-payload and conjugation technology GeneQuantum provides proved to be very safe and effective.

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target

Retrieved on: 
Wednesday, April 13, 2022
Kite Pharma, CD205, Wuxi, Boehringer Ingelheim, OBT, BMS, Patient, Clinical trial, SAN, Antibody-drug conjugate, Amgen, Cytotoxicity, ADCC, Neoplasm, NK, Partnership, ADC, Cancer, Therapy, Fine chemical, Vaccine, IO

Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.

Key Points: 
  • Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.
  • OBT will receive development and regulatory milestone payments as well as royalties on any future product sales.
  • This represents the third asset to be optioned under the longstanding partnership between OBT and Boehringer Ingelheim, with the first two programs already in clinical development.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target

Retrieved on: 
Wednesday, April 13, 2022
Kite Pharma, CD205, Wuxi, Boehringer Ingelheim, OBT, BMS, Patient, Clinical trial, SAN, Antibody-drug conjugate, Amgen, Cytotoxicity, ADCC, Neoplasm, NK, Partnership, ADC, Cancer, Therapy, Fine chemical, Vaccine, IO

Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.

Key Points: 
  • Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target.
  • OBT will receive development and regulatory milestone payments as well as royalties on any future product sales.
  • This represents the third asset to be optioned under the longstanding partnership between OBT and Boehringer Ingelheim, with the first two programs already in clinical development.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.

AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076

Retrieved on: 
Thursday, April 7, 2022
Cancer, CD205, Experiment, Diagnosis, CD45, Oxford, CPI, ADC, Adult, Primary tumor, CMO, AACR, Doctor of Philosophy, CD4, American Association, PD, Lymph, Neoplasm, CEO, Antibody-drug conjugate, Translation, Ascites, CD8, MD, Immune system, Flow cytometry, OBT, Stomach, SAN, American Association for Cancer Research, Patient, Pharmaceutical industry, Vaccine, Medical imaging

"The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.

Key Points: 
  • "The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.
  • Following 2 further cycles of OBT076 and 1 cycle of CPI, complete response was achieved for the primary tumor.
  • These data give us hope that OBT076 could achieve favorable clinical outcomes in such patients when used in combination with immune CPIs.
  • The abstract and presentation details are as follows:
    Title: Potential Novel Immuno-oncology Mechanism revealed during Translational Phase I Immuno- blood Profiling of Experimental ADC medicine OBT076 in A Gastric Cancer Patient.

AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076

Retrieved on: 
Thursday, April 7, 2022
Cancer, CD205, Experiment, Diagnosis, CD45, Oxford, CPI, ADC, Adult, Primary tumor, CMO, AACR, Doctor of Philosophy, CD4, American Association, PD, Lymph, Neoplasm, CEO, Antibody-drug conjugate, Translation, Ascites, CD8, MD, Immune system, Flow cytometry, OBT, Stomach, SAN, American Association for Cancer Research, Patient, Pharmaceutical industry, Vaccine, Medical imaging

"The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.

Key Points: 
  • "The results support our excitement around OBT076 as a therapeutic capable of harnessing the immune system to treat patients with advanced, difficult to treat cancers both as monotherapy and in combination with a CPI.
  • Following 2 further cycles of OBT076 and 1 cycle of CPI, complete response was achieved for the primary tumor.
  • These data give us hope that OBT076 could achieve favorable clinical outcomes in such patients when used in combination with immune CPIs.
  • The abstract and presentation details are as follows:
    Title: Potential Novel Immuno-oncology Mechanism revealed during Translational Phase I Immuno- blood Profiling of Experimental ADC medicine OBT076 in A Gastric Cancer Patient.

Bio-Thera Solutions Announces First Patient Dosed in a Phase 1 Study in Australia Evaluating BAT6026, an Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, an Anti-PD-1 Antibody

Retrieved on: 
Wednesday, March 30, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ADCC, IO, Folate, Therapy, Degenerative disease, Marketing, Trial of the century, Forward-looking statement, Pharmacokinetics, ADC, Autoimmunity, Pharmacology, CD47, IND, Neoplasm, Cancer, Antibody-drug conjugate, CEO, Solution, PD-1, OX40, Safety, TIGIT, Intellectual property, News, Pharmacy, Engineering, Patient, Folate receptor, Vaccine, Pharmaceutical industry

BAT6026 has demonstrated highly potent anti-tumor activity as a single agent and in combination with BAT1308 in in vivo pharmacology studies.

Key Points: 
  • BAT6026 has demonstrated highly potent anti-tumor activity as a single agent and in combination with BAT1308 in in vivo pharmacology studies.
  • BAT6026 has demonstrated potent Treg depletion activity, while synergistically activating T effector cells.
  • Key objectives in the study include determining maximum tolerated dose and recommended Phase 2 dose (RP2D), pharmacokinetics and preliminary anti-tumor activity in combination therapy.
  • This news release contains certain forward-looking statements relating to BAT6026, BAT1308 or the product pipelines in general of Bio-Thera Solutions.

Elucida Oncology to Present at Two Upcoming Scientific Conferences

Retrieved on: 
Thursday, March 3, 2022
Toxicity, Patient, Industry, CDC classification system for HIV infection, Festival, Congress, Cancer, Conference, Target, Drug, Neoplasm, Antibody-drug conjugate, Control, CDC, FRA, GLOBE, Vaccine

Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug conjugate (CDC) platform.

Key Points: 
  • Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle CDot drug conjugate (CDC) platform.
  • CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs).
  • This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear properties.
  • In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.

OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

Retrieved on: 
Tuesday, February 22, 2022
Lung, NSCLC, Therapy, Globo, Risk, Globo H, Immune system, Neoplasm, Oncology, Private Securities Litigation Reform Act, Safety, Cancer, OBI, AKR1C3, Lists of diseases, Immunoglobulin G, IND, DAR, Breast, OBI Pharma, Inc., Patient, Securities and Futures Bureau, Large-cell lung carcinoma, Autoimmunity, PK, Antibody-drug conjugate, Prostate, ADC, Vaccine, Pharmaceutical industry, Odeon

Under the terms of the agreement, OBI will grant Odeon exclusive rights to develop, register and commercialize OBI-999 and OBI-833 for human cancer therapy in China, Hong Kong and Macao.

Key Points: 
  • Under the terms of the agreement, OBI will grant Odeon exclusive rights to develop, register and commercialize OBI-999 and OBI-833 for human cancer therapy in China, Hong Kong and Macao.
  • Odeon will also be responsible for all development costs and all subsequent regulatory and commercialization costs of OBI-999 and OBI-833 in China, Hong Kong and Macao.
  • "We are excited to announce the license agreement which enables Odeon to develop, register and commercialize novel 1st-in-class anti-Globo H targeted Oncology therapeutics, OBI-999 and OBI-833 in China, Hong Kong and Macau," stated Kevin Poulos, Chief Commercial Officer OBI Pharma.
  • OBI Pharma has no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise."

OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

Retrieved on: 
Tuesday, February 22, 2022
Lung, NSCLC, Therapy, Globo, Risk, Globo H, Immune system, Neoplasm, Oncology, Private Securities Litigation Reform Act, Safety, Cancer, OBI, AKR1C3, Lists of diseases, Immunoglobulin G, IND, DAR, Breast, OBI Pharma, Inc., Patient, Securities and Futures Bureau, Large-cell lung carcinoma, Autoimmunity, PK, Antibody-drug conjugate, Prostate, ADC, Vaccine, Pharmaceutical industry, Odeon

TAIPEI, Taiwan, Feb. 22, 2022 /PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into an exclusive license agreement whereby OBI grants rights of OBI-999, a novel antibody-drug conjugate, and OBI-833, a therapeutic cancer vaccine, targeting the tumor antigen Globo H in China, Hong Kong and Macau to Odeon.

Key Points: 
  • Under the terms of the agreement, OBI will grant Odeon exclusive rights to develop, register and commercialize OBI-999 and OBI-833 for human cancer therapy in China, Hong Kong and Macao.
  • Odeon will also be responsible for all development costs and all subsequent regulatory and commercialization costs of OBI-999 and OBI-833 in China, Hong Kong and Macao.
  • "We are excited to announce the license agreement which enables Odeon to develop, register and commercialize novel 1st-in-class anti-Globo H targeted Oncology therapeutics, OBI-999 and OBI-833 in China, Hong Kong and Macau," stated Kevin Poulos, Chief Commercial Officer OBI Pharma.
  • OBI Pharma has no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise."